Metabolic · Peptide (once-weekly injection)

Retatrutide

Retatrutide is an experimental once-weekly injection that activates three hormone receptors. It produced some of the largest weight reductions seen in obesity trials. Lilly says its data package is complete and plans an FDA filing in early 2027.

Not yet approvedPhase 3 obesity program complete; Lilly plans to file with the FDA in Q1 2027

Not yet approved: Not approved for any use. The drug is still being tested in clinical trials. About status badges

FDA: Not approved. No approved application appears in openFDA as of Nov 19, 2026 (openFDA lists approved applications only, so a pending submission would not appear). In the United States, this drug is investigational.

DeveloperEli Lilly and Company · Eli Lilly and Company pipeline
Drug typePeptide (once-weekly injection)
TargetGIP, GLP-1, and glucagon receptors
MechanismActivates three hormone receptors (GIP, GLP-1, and glucagon), reducing appetite and increasing energy expenditure
Other namesLY3437943

Key points

  • Retatrutide is a 'triple agonist': one molecule that activates the GIP, GLP-1, and glucagon receptors.
  • In the 338-patient Phase 2 trial, the 12 mg dose reduced body weight by 24.2% at 48 weeks, compared with 2.1% with placebo.
  • Lilly reported that in the Phase 3 TRIUMPH-1 trial, participants on 12 mg lost an average of 28.3% of body weight over 80 weeks (company-reported topline).
  • In August 2026, Lilly said its clinical data package was complete and that it plans to submit to the FDA in the first quarter of 2027.
  • Retatrutide is not approved anywhere. Lilly has publicly warned against products sold illegally under its name.

Development programs

Each disease a drug is tested for is a separate program, with its own evidence and its own odds.

IndicationStageRegistered trialsHistorical benchmark
Obesity and overweight
TRIUMPH-1, -2, -3 and -4 are complete (registry). Lilly plans a BLA submission in Q1 2027 (company-reported).
Phase 3 (submission planned, company-reported)17
6 active · 10 completed
52.4% eventual approval
Phase 3 → application: 57.8%
Type 2 diabetes
Lilly reported positive topline results from a head-to-head Phase 3 trial against Ozempic 2 mg (company-reported, October 2026).
Phase 38
3 active · 5 completed
52.4% eventual approval
Phase 3 → application: 57.8%
Cardiovascular, kidney, liver and other indications
Includes the 10,000-participant cardiovascular and kidney outcomes trial and a master protocol in metabolic liver disease (registry).
Phase 34
2 active · 2 completed
52.4% eventual approval
Phase 3 → application: 57.8%

Historical benchmarks are industry-wide averages for programs at the same stage, 2011–2020 (BIO, Informa, QLS; eventual-approval figures are from the report’s likelihood-of-approval table, Figure 5b). They are not predictions for this drug. We use all-indication rates because the source does not define which conditions fall in each disease area; see the therapeutic area pages for area-level rates. Benchmarks are withheld where they would mislead, for example after approval or after a failed pivotal trial. See our methodology.

What retatrutide is

Retatrutide is a once-weekly injectable peptide developed by Eli Lilly. It is a triple agonist: a single molecule that activates three hormone receptors involved in appetite and metabolism:

Receptor Main effects relevant to weight
GLP-1 (glucagon-like peptide-1) Reduces appetite and slows stomach emptying; the target of semaglutide
GIP (glucose-dependent insulinotropic polypeptide) Adds to GLP-1's effects on appetite and blood sugar; tirzepatide targets GIP and GLP-1
Glucagon May increase energy expenditure and affect liver fat

Adding glucagon receptor activity to the GIP and GLP-1 combination is what distinguishes retatrutide from approved incretin drugs.

Clinical evidence

Phase 2

In a 48-week Phase 2 trial of 338 adults with obesity, published in the New England Journal of Medicine in 2023, weight loss increased with dose:

Dose Change in body weight at 48 weeks
1 mg −8.7%
4 mg (combined groups) −17.1%
8 mg (combined groups) −22.8%
12 mg −24.2%
Placebo −2.1%

At 48 weeks, 83% of participants on 12 mg had lost at least 15% of their body weight, compared with 2% on placebo. The most common adverse events were gastrointestinal. These were dose-related and mostly mild to moderate, and a lower starting dose partly reduced them. Heart rate rose with dose, peaked at 24 weeks, and declined thereafter.

Phase 3: the TRIUMPH program

Lilly's Phase 3 obesity program, TRIUMPH, includes several large trials. ClinicalTrials.gov lists TRIUMPH-1 (2,335 participants), TRIUMPH-2 (type 2 diabetes), TRIUMPH-3 (cardiovascular disease), and TRIUMPH-4 (knee osteoarthritis) as complete.

On May 21, 2026, Lilly reported that in TRIUMPH-1, participants taking the 12 mg dose lost an average of 28.3% of body weight over 80 weeks. This is a company-reported topline figure. Full peer-reviewed results will allow the effect to be compared across analysis methods and against placebo in detail.

In its August 2026 quarterly report, filed with the SEC, Lilly stated that "the clinical data package is now complete to support global registrations for obesity," with plans to submit a Biologics License Application to the FDA in the first quarter of 2027. In October 2026, Lilly reported positive topline results from a head-to-head Phase 3 trial of retatrutide versus semaglutide (Ozempic 2 mg) in type 2 diabetes.

Scientific perspective

Retatrutide's Phase 2 and reported Phase 3 results place it among the most effective weight-loss medicines ever tested. The scientific questions now concern how the effect is achieved and at what cost:

  • Tolerability. Gastrointestinal effects are common to the whole drug class. Whether the highest doses are tolerable for long-term use is central to how widely the drug would be used.
  • Heart rate. Phase 2 showed dose-dependent heart-rate increases that later declined. Long-term cardiovascular safety will be assessed in the dedicated outcomes trial.
  • Body composition. With very large weight loss, the proportion of lean tissue lost, and its consequences, is an active research question for the class.
  • Durability. As with other incretin drugs, weight regain after stopping is likely. A maintenance trial, TRIUMPH-6, is listed as active.

Development perspective

  • Regulatory status: not approved by the FDA or, to our knowledge, any regulator. openFDA lists no application record.
  • Next milestone: BLA submission, planned for Q1 2027 (company-reported). The FDA's standard review goal for a new molecular entity is 10 months after its 60-day filing period, or about 12 months from submission. See How Does the FDA Approve New Drugs?
  • Historical benchmark: programs that have reached Phase 3 have historically had about a 52% chance of eventual approval. Retatrutide's completed Phase 3 obesity trials and reported results put it in a stronger position than an average Phase 3 program, but benchmarks do not adjust for drug-specific evidence.
  • Illegal products: Lilly has publicly called on online platforms, payment companies, and regulators to shut down what it calls an illegal retatrutide black market (October 2026 SEC filing). Products sold as "retatrutide" outside clinical trials are not approved and have not been evaluated for quality or safety.

Competitive context

Retatrutide would enter a market led by Lilly's own tirzepatide (Zepbound, Mounjaro) and Novo Nordisk's semaglutide, alongside Lilly's oral GLP-1 drug orforglipron (Foundayo). Its potential advantage is greater weight loss. Its challenges will be tolerability, pricing, and showing benefits beyond weight, which Lilly is studying in osteoarthritis, sleep apnea, kidney, and cardiovascular outcomes trials.

Development timeline

  1. May 20, 2021Phase 2 obesity trial begins (338 participants). Registry
  2. Jun 26, 2023Phase 2 results published: −24.2% body weight at 48 weeks on 12 mg, versus −2.1% with placebo. Peer-reviewed
  3. Jul 10, 2023TRIUMPH-1 Phase 3 obesity trial begins. Registry
  4. Apr 30, 2024Cardiovascular and kidney outcomes trial begins (estimated 10,000 participants). Registry
  5. May 21, 2026Lilly reports TRIUMPH-1 topline results: average weight loss of 28.3% at 80 weeks on 12 mg. Company-reported
  6. Aug 5, 2026Lilly states the data package is complete to support global registrations for obesity, with plans to submit a BLA to the FDA in Q1 2027. Company-reported
  7. Oct 29, 2026Lilly reports positive topline results from a head-to-head Phase 3 trial of retatrutide versus Ozempic 2 mg. Company-reported

What could change the outlook

  • Submission of the Biologics License Application, which Lilly plans for Q1 2027, and FDA acceptance for review.
  • Peer-reviewed publication of the full TRIUMPH results, including safety and tolerability details beyond the topline releases.
  • Tolerability at the highest doses: gastrointestinal effects and heart-rate increases were dose-related in Phase 2.
  • Results of the 10,000-participant cardiovascular and kidney outcomes trial (registry estimates primary completion in February 2029).
  • Head-to-head data against tirzepatide (TRIUMPH-5, active per the registry).

Latest company disclosures

Company press releases (SEC filings and PR Newswire) that mention Retatrutide. Company-reported, not independently verified.

  1. Quarterly reportCompany-reportedOct 29, 2026

    Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio

    “Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound, the global launches of Foundayo, expanded U.S. coverage for obesity care and a doubling in our newest products in oncology, immunology and neuroscience.

    Source
    SEC Form 8-K · Financial results
  2. Trial resultsCompany-reportedOct 28, 2026

    Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial

    Eli Lilly and Company (NYSE: LLY ), the maker of Mounjaro (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRANSCEND-T2D-2, a head-to-head Phase 3 trial comparing retatrutide with injectable Ozempic 2 mg in adults with type 2 diabetes.

  3. Trial resultsCompany-reportedSep 29, 2026

    Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes

    Eli Lilly and Company (NYSE: LLY ), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced detailed results from TRIUMPH-2, a Phase 3 trial evaluating the efficacy and safety of retatrutide, an investigational, first-in-class GIP, GLP-1 , and glucagon triple hormone receptor agonist, in...

All Retatrutide disclosures in Pipeline News

Clinical trials

34 registered trials list Retatrutide as an intervention, retrieved from ClinicalTrials.gov on Nov 19, 2026. Status, dates, and enrollment are as reported by sponsors to the registry. “Est.” marks anticipated values.

Obesity and overweight

TrialPhaseStatusEnrollmentPrimary completionResults posted
TRIUMPH-1 · NCT05929066
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
Phase 3Completed2,335Apr 6, 2026No
TRIUMPH-3 · NCT05882045
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Phase 3Completed1,946Apr 16, 2026No
TRIUMPH-2 · NCT05929079
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Phase 3Completed1,152Jun 16, 2026No
TRIUMPH-5 · NCT06662383
A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
Phase 3Active, not recruiting800 (est.)Nov 2026 (est.)No
TRIUMPH-6 · NCT06859268
A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
Phase 3Active, not recruiting643 (est.)Apr 2028 (est.)No
TRIUMPH-9 · NCT07357415
A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
Phase 3Active, not recruiting600 (est.)Oct 2028 (est.)No
TRIUMPH-7 · NCT07035093
A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Phase 3Active, not recruiting586 (est.)Sep 2027 (est.)No
TRIUMPH-4 · NCT05931367
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee
Phase 3Completed445Nov 14, 2025No
TRIUMPH-8 · NCT07232719
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
Phase 3Active, not recruiting250 (est.)Jun 2027 (est.)No
NCT04881760
A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
Phase 2Completed338May 16, 2022Yes
GZBF · NCT07467447
Effect of Retatrutide Versus Placebo in Participants Who Have Obesity or Are Overweight
Phase 2Recruiting300 (est.)Mar 14, 2027 (est.)No
NCT05936151
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Phase 2Completed146Oct 1, 2025Yes
5 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06313528
A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943
Phase 1Completed85Aug 26, 2025No
NCT06039826
A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
Phase 1Completed46Jul 11, 2024No
NCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
Phase 1Completed32Feb 24, 2023No
NCT05548231
A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
Phase 1Completed32Jul 27, 2023No
NCT07629401
Pre-approval Expanded Access of Retatrutide (LY3437943)
N/AAVAILABLE——No

Type 2 diabetes

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06260722
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Phase 3Active, not recruiting1,250 (est.)Aug 27, 2026No
NCT06354660
Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)
Phase 3Completed537Jan 22, 2026No
NCT06297603
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
Phase 3Active, not recruiting341Oct 26, 2026No
NCT04867785
A Study of LY3437943 in Participants With Type 2 Diabetes
Phase 2Completed281Jul 8, 2022Yes
4 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06982859
A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus
Phase 1Active, not recruiting95 (est.)Jan 2027 (est.)No
NCT06982846
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
Phase 1Completed80May 4, 2026No
NCT04143802
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
Phase 1Completed72Dec 28, 2020No
NCT04823208
A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
Phase 1Completed64Jun 23, 2022No

Cardiovascular, kidney, liver and other indications

TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT06383390
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
Phase 3Active, not recruiting10,000 (est.)Feb 2029 (est.)No
NCT07165028
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
Phase 3Recruiting4,500 (est.)Aug 2030 (est.)No
2 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT05916560
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Phase 1Completed43Mar 2, 2025No
NCT05611957
A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
Phase 1Completed29Sep 5, 2023No

Clinical pharmacology and supporting studies

5 Phase 1 or other early-stage studies
TrialPhaseStatusEnrollmentPrimary completionResults posted
NCT05959096
A Study of LY3437943 in Healthy Participants With a High Body Mass Index
Phase 1Completed85Jul 25, 2024No
NCT06003465
A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
Phase 1Completed57Feb 8, 2024No
NCT03841630
A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
Phase 1Completed45Jul 25, 2019No
NCT06808802
To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants
Phase 1Completed30Apr 15, 2025No
NCT05757531
A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
Phase 1Completed7Jun 23, 2023No

No registry changes detected since tracking began on Nov 19, 2026. Future status, date, and endpoint changes will be logged here.

Sources

  1. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a Phase 2 trial. New England Journal of Medicine. 2023;389(6):514–526.Peer-reviewed
  2. Eli Lilly and Company. Retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial (May 21, 2026).Company-reported
  3. Eli Lilly and Company. Form 8-K: Q2 2026 results (August 5, 2026).Company-reported
  4. Eli Lilly and Company. Form 8-K: Q3 2026 results (October 29, 2026).Company-reported
  5. ClinicalTrials.gov. TRIUMPH-1 (NCT05929066).Registry
  6. ClinicalTrials.gov. Retatrutide cardiovascular and kidney outcomes trial (NCT06383390).Registry
  7. BIO, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report

This profile is for education and research. It is not medical advice and not investment advice, and nothing here is a recommendation to buy or sell any security. Company-reported results are labeled and have not necessarily been peer reviewed. See our editorial standards and disclaimer.